Role of tumor markers and circulating tumors cells in the management of breast cancer

ONCOLOGY

Volumn 22, Issue 7, 2008, Pages 726-731

  Saad, Ayman ^a   Abraham, Jame ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CALCIUM; CARCINOEMBRYONIC ANTIGEN; DEOXYPYRIDINOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MUCIN 1; SURVIVIN; TRASTUZUMAB; TUMOR MARKER;

BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CELL ISOLATION; CLINICAL PROTOCOL; CLINICAL TRIAL; FOLLOW UP; HUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; TUMOR LOCALIZATION;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM CIRCULATING CELLS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 47549116585     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
2. Hodgson NC, Gulenchyn KY: Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 26:712-720,2008.
3. Duffy MJ: Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345-351, 2006.
4. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14:2843-2877, 1996.
5. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007.
6. FDA approves first blood test for breast cancer recurrence FDA Med Bull 26(2), 1996.
7. Beveridge RA: Review of clinical studies of CA 27.29 in breast cancer management. Int J Biol Markers 14:36-39, 1999.
8. Price MR, Hudecz F, O'Sullivan C, et al: Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 27:795-802, 1990.
9. Briggs S, Price MR, Tendier SJ: Immune recognition of linear epitopes in peptide fragments of epithelial mucins. Immunology 73:505-507, 1991.
10. Klee GG, Schreiber WE: MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): Are they measuring the same antigen? Arch Pathol Lab Med 128:1131-1135, 2004.
11. Lufter D, Richter A, Gunther S, et al: A comparison of bone-related biomarkers and CA27 29 to assess response to treatment of osseous metastatic breast cancer. Anticancer Res 20:5099-5105, 2000.
12. Gion M, Mione R, Leon AE, et al: CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 37:355-363, 2001.
13. Duffy MJ, Duggan C, Keane R, et al: High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer. Clin Chem 50:559-563, 2004.
14. Kumpulainen EJ, Keskikuru RJ, Johansson RT: Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 76:95-102, 2002.
15. Veronesi A, Talamini R, Longhi S, et al: Carcinoembryonic antigen (CEA) in the follow-up of disease-free breast cancer patients. Tumori 68:477-480, 1982.
16. Tondini C, Hayes DF, Gelman R, et al: Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107-4112, 1988.
17. Hou MF, Chen YL, Tseng TF, et al: Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci 15:520-528, 1999.
18. Khatcheressian JL, Wolff AC, Smith TJ, et al: American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24:5091-5097, 2006.
19. Carney WP, Neumann R, Lipton A, et al: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49:1579-1598, 2003.
20. Meng S, Tripathy D, Frenkel EP, et al: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152-8162, 2004.
21. Candar Z, Ritchie AC, Hopkirk JF, et al: The prognostic value of circulating tumor cells in patients with breast cancer. Surg Gynecol Obstet 115:291-294, 1962.
22. Webster DR, Sabbadini E: The prognostic significance of circulating tumour cells: A five-year follow-up study of patients with cancer of the breast. Can Med Assoc J 96:129-131, 1967.
23. Pachmann K, Clement JH, Schneider CP, et al: Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 43:617-627, 2005.
24. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904, 2004.
25. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004.
26. Hayes DF, Cristofanilli M, Budd GT, et al: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218-4224, 2006.
27. Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420-1430, 2005.
28. Nassar A, Lawson D, Cotsonis G, et al: Survivin and caspase-3 expression in breast cancer: Correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol 16:221-226, 2008.
29. Yie SM, Luo B, Ye NY, et al: Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis 23:279-289, 2006.
30. Budd GT, Cristofanilli M, Ellis MJ, et al: Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res 12:6403-6409, 2006.
31. Stopeck A, Cristofanilli M, Budd GT, et al: Circulating tumor cells - not serum tumor markers - predict survival in metastatic breast cancer (abstract 9516). J Clin Oncol 23(16S):840s, 2005.
32. Beveridge R: Circulating tumor cells in the management of metastatic breast cancer patients Community Oncology 4:79-82, 2007.
33. Saad A, Kanate A, Rikhye S, et al: Correlation among FDG-PET/CT, tumor marker CA 27.29, and circulating tumor cell test in metastatic breast cancer Clin Breast Cancer. In press.
34. Mueller V, Riethdorf S, Loibl S, et al: Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy - a translational project of the German Breast Group study GeparQuattro (abstract 21085). J Clin Oncol 25(18S):735s, 2007.
35. Pachmann K, Camara O, Kavallaris A, et al: Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: A new tool for therapy monitoring. Breast Cancer Res 7:R975-R979, 2005.
36. Rack BK, Schindlbeck C, Hofmann S, et al: Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients (abstract 10595). J Clin Oncol 25(18S):588s, 2007.
37. Molina R, Barak V, van Dalen A, et al: Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 26:281-293, 2005.
38. Perkins GL, Slater ED, Sanders GK, et al: Serum tumor markers. Am Fam Physician 68:1075-1082, 2003.
39. Cristofanilli M: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol 33:S9-S14, 2006.